Presented by: Dr Marco Herold, Laboratory Head, Molecular Genetics of Cancer Division, The Walter & Eliza Hall Institute of Medical Research
Abstract: The CRISPR/Cas9 technology provides an easy and rapid way to edit genes in vitro and in vivo. Initial experimental strategies utilized a transient transfection approach to modulate genes in vitro, but this proved to have a low efficiency and was not broadly applicable to all cell types. In order to modify genes in the haematopoietic system we have developed a novel drug-inducible lentiviral system to deliver the CRISPR/Cas9 platform to cells permitting efficient genome engineering in vitro and in vivo.